MAGE-A gene expression pattern in primary breast cancer

Cancer Research

Volumn 61, Issue 18, 2001, Pages 6682-6687

  Otte, Marcus ^a   Zafrakas, Menelaos ^a   Riethdorf, Lutz ^c   Pichlmeier, Uwe ^b   Löning, Thomas ^c   Jänicke, Fritz ^a   Pantel, Klaus ^a  

^a Molekulare Onkologie ^*  (Germany)

^b Institut für Mathematik und Datenverarbeitung in der Medizin   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; MELANOMA ANTIGEN; MELANOMA ANTIGEN A; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RISK; CLINICAL FEATURE; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; TUMOR GROWTH;

ADULT; AGED; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL DIVISION; FEMALE; GENE EXPRESSION; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS;

EID: 0035884426     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
2. Structure, chromosomal localization, and expression of 12 genes of the MAGE family
3. Identification of MAGE-1 and MAGE-4 proteins in spermatogenia and primary spermatocytes of testis
4. The potential of melanoma antigen expression in cancer therapy
5. Tumor regression observed in patients with metastatic melanoma treated with an antigenic peptide encode by gene MAGE-3 and presented by HLA-Al
6. A Phase I trial of an HLA-Al restricted MAGE-3 epitope peptide with incomplete Freund’s adjuvant in patients with resected high-risk melanoma
7. Vaccination with MAGE-3Al peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T-cells and induces regression of some metastases in advanced stage IV melanoma
8. HLA-independent heterogeneity of CD8+ T-cell responses to MAGE-3, Melan A/MART-1, gp 100, Tyrosinase, MCIR, and TRP-2 in vaccine-treated melanoma patients
9. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine
10. The activation of human gene MAGE-1 in tumor cells correlated with genome-wide demethylation
11. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse
12. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
13. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: Establishment of working models for human micrometastases
14. Expression of MAGE-antigens in normal tissues and cancer
15. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors
16. Expression of the MAGE gene family in primary and metastatic human breast cancer: Implications for tumor antigen-specific immunotherapy
17. Detection of MAGE-1, -2, and -3 messenger RNA in tissue samples derived from lung and mammary tumors
18. Expression of MAGE and BAGE genes in Japanese breast cancers
19. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer
20. Global DNA hypomethylation in breast carcinoma: Correlation with prognostic factors and tumor progression